Chongqing, China, China
Chongqing Precision Biotech Co., Ltd is a Chinese biopharmaceutical company focused on precision medicine and drug development.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
15 drugs in development
By Therapeutic Area
top 3
R&D Momentum
59/100
Pipeline Velocity
22/100
Trial Completion Rate
67/100
Pipeline Concentration
38/100
Pipeline Freshness
65/100
Strategic Signals
Activity
Last 14 days
A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Clinical Study of CD70-Targeted Chimeric Antigen Receptor T Lymphocytes (CAR-T) in Advanced CD70-Positive Malignant Solid Tumors
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)